Moreover, recent ASCO/CAP guidelines (2021) suggest NAT should be prescribed for the vast majority of patients with HER2+ breast cancer, with exceptions limited to those with T1a/N0 and T1bN0 disease (unless recruited into clinical trial settings) [47]. The gene discussed is ERBB2; the disease is breast carcinoma.